Stockreport

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Cognition Therapeutics, Inc.  (CGTX) 
PDF Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup 2025 Objective: Advance Zervimesine [Read more]